 Toby Trujillo
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 22 | 2023 | 559 | 3.850 |
Why?
| | Venous Thromboembolism | 16 | 2022 | 234 | 3.130 |
Why?
| | Factor Xa Inhibitors | 6 | 2021 | 138 | 1.680 |
Why?
| | Acute Coronary Syndrome | 4 | 2020 | 257 | 1.510 |
Why?
| | Hemorrhage | 10 | 2022 | 623 | 1.290 |
Why?
| | Thrombosis | 6 | 2023 | 309 | 1.170 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2023 | 402 | 1.100 |
Why?
| | Students, Pharmacy | 2 | 2016 | 99 | 1.000 |
Why?
| | Pharmacy Residencies | 2 | 2014 | 11 | 0.980 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2023 | 14 | 0.950 |
Why?
| | Education, Pharmacy | 2 | 2016 | 130 | 0.940 |
Why?
| | Blood Coagulation | 4 | 2021 | 219 | 0.920 |
Why?
| | Geriatrics | 1 | 2023 | 68 | 0.900 |
Why?
| | Atrial Fibrillation | 4 | 2022 | 338 | 0.880 |
Why?
| | Percutaneous Coronary Intervention | 2 | 2020 | 455 | 0.810 |
Why?
| | Warfarin | 3 | 2022 | 139 | 0.800 |
Why?
| | Piperazines | 4 | 2019 | 316 | 0.770 |
Why?
| | Blood Coagulation Factors | 1 | 2020 | 43 | 0.740 |
Why?
| | Factor Xa | 4 | 2021 | 31 | 0.680 |
Why?
| | Vitamin K | 1 | 2019 | 44 | 0.670 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 208 | 0.640 |
Why?
| | Angina Pectoris | 2 | 2007 | 63 | 0.620 |
Why?
| | Acetanilides | 2 | 2007 | 11 | 0.610 |
Why?
| | Dalteparin | 2 | 2014 | 9 | 0.590 |
Why?
| | Fibrinolytic Agents | 2 | 2014 | 238 | 0.560 |
Why?
| | Practice Guidelines as Topic | 6 | 2020 | 1440 | 0.530 |
Why?
| | Thrombocytopenia | 2 | 2014 | 185 | 0.510 |
Why?
| | Antithrombins | 4 | 2020 | 51 | 0.510 |
Why?
| | Thiophenes | 2 | 2014 | 106 | 0.500 |
Why?
| | Morpholines | 2 | 2014 | 106 | 0.500 |
Why?
| | Cardiovascular Diseases | 5 | 2023 | 1798 | 0.490 |
Why?
| | Patient-Centered Care | 2 | 2016 | 497 | 0.480 |
Why?
| | Recombinant Proteins | 6 | 2021 | 1308 | 0.480 |
Why?
| | Rivaroxaban | 7 | 2022 | 208 | 0.470 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 827 | 0.460 |
Why?
| | Humans | 53 | 2023 | 118974 | 0.430 |
Why?
| | Administration, Oral | 7 | 2022 | 756 | 0.410 |
Why?
| | Arginine | 5 | 2020 | 249 | 0.380 |
Why?
| | Pyridones | 5 | 2021 | 119 | 0.370 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2010 | 148 | 0.350 |
Why?
| | Myocardial Infarction | 2 | 2020 | 968 | 0.340 |
Why?
| | Fibrinolysis | 1 | 2010 | 159 | 0.330 |
Why?
| | Pyrazoles | 5 | 2021 | 363 | 0.320 |
Why?
| | Electric Countershock | 2 | 2019 | 110 | 0.310 |
Why?
| | Arrhythmias, Cardiac | 1 | 2010 | 277 | 0.310 |
Why?
| | Heparin | 4 | 2016 | 230 | 0.300 |
Why?
| | Angina, Stable | 1 | 2006 | 17 | 0.290 |
Why?
| | Aged | 13 | 2023 | 19657 | 0.290 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2006 | 20 | 0.290 |
Why?
| | Thrombin | 2 | 2020 | 143 | 0.280 |
Why?
| | Drug Interactions | 5 | 2016 | 352 | 0.270 |
Why?
| | Pharmacists | 3 | 2014 | 238 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2020 | 1244 | 0.270 |
Why?
| | Sucrose | 1 | 2005 | 104 | 0.260 |
Why?
| | Thromboembolism | 2 | 2016 | 99 | 0.250 |
Why?
| | Diet | 1 | 2012 | 1153 | 0.240 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2005 | 128 | 0.240 |
Why?
| | Pipecolic Acids | 3 | 2020 | 22 | 0.240 |
Why?
| | Dabigatran | 4 | 2016 | 26 | 0.240 |
Why?
| | Hirudins | 3 | 2020 | 46 | 0.240 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 667 | 0.230 |
Why?
| | Inappropriate Prescribing | 1 | 2023 | 51 | 0.230 |
Why?
| | Middle Aged | 10 | 2023 | 27617 | 0.210 |
Why?
| | Antiphospholipid Syndrome | 1 | 2021 | 29 | 0.200 |
Why?
| | Aspirin | 2 | 2023 | 334 | 0.200 |
Why?
| | Coronary Artery Disease | 1 | 2007 | 647 | 0.200 |
Why?
| | Prothrombin | 1 | 2021 | 21 | 0.200 |
Why?
| | Aged, 80 and over | 4 | 2021 | 6561 | 0.190 |
Why?
| | Pharmaceutical Services | 2 | 2013 | 79 | 0.190 |
Why?
| | Male | 16 | 2023 | 57801 | 0.190 |
Why?
| | Neoplasms | 1 | 2014 | 2179 | 0.180 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 113 | 0.180 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 66 | 0.180 |
Why?
| | Female | 16 | 2023 | 61565 | 0.180 |
Why?
| | Stroke | 2 | 2022 | 1047 | 0.180 |
Why?
| | Intracranial Hemorrhages | 1 | 2020 | 77 | 0.180 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2020 | 109 | 0.180 |
Why?
| | Communication | 2 | 2016 | 761 | 0.180 |
Why?
| | Peptide Fragments | 3 | 2020 | 702 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2022 | 197 | 0.170 |
Why?
| | Chi-Square Distribution | 1 | 2020 | 525 | 0.170 |
Why?
| | Secondary Prevention | 1 | 2020 | 227 | 0.170 |
Why?
| | Blood Coagulation Tests | 2 | 2016 | 58 | 0.170 |
Why?
| | Electrodiagnosis | 1 | 2018 | 15 | 0.170 |
Why?
| | Adult | 9 | 2023 | 31512 | 0.170 |
Why?
| | Retrospective Studies | 8 | 2022 | 12978 | 0.170 |
Why?
| | Goals | 1 | 2020 | 167 | 0.160 |
Why?
| | Hospitalization | 2 | 2020 | 1785 | 0.160 |
Why?
| | Critical Illness | 1 | 2023 | 662 | 0.160 |
Why?
| | Acute Kidney Injury | 1 | 2005 | 709 | 0.160 |
Why?
| | Ranolazine | 2 | 2007 | 21 | 0.150 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 965 | 0.150 |
Why?
| | Healthcare Disparities | 2 | 2014 | 496 | 0.150 |
Why?
| | Chronic Disease | 3 | 2007 | 1636 | 0.150 |
Why?
| | Electrocardiography | 2 | 2010 | 556 | 0.150 |
Why?
| | Partial Thromboplastin Time | 2 | 2014 | 52 | 0.150 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 969 | 0.140 |
Why?
| | Coronary Disease | 1 | 1998 | 356 | 0.140 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 485 | 0.130 |
Why?
| | Catheter Ablation | 1 | 2019 | 286 | 0.130 |
Why?
| | United States | 5 | 2020 | 12555 | 0.130 |
Why?
| | Medicare | 1 | 2020 | 663 | 0.130 |
Why?
| | Educational Measurement | 1 | 2016 | 289 | 0.120 |
Why?
| | Venous Thrombosis | 1 | 2016 | 147 | 0.120 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 87 | 0.120 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 79 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2016 | 183 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1945 | 0.120 |
Why?
| | Treatment Outcome | 5 | 2020 | 9342 | 0.110 |
Why?
| | Perioperative Care | 2 | 2014 | 132 | 0.110 |
Why?
| | Hip Joint | 1 | 2014 | 144 | 0.110 |
Why?
| | Emergency Treatment | 1 | 2013 | 110 | 0.110 |
Why?
| | History, 21st Century | 1 | 2013 | 170 | 0.110 |
Why?
| | Edible Grain | 1 | 2012 | 43 | 0.110 |
Why?
| | Glycemic Index | 1 | 2012 | 24 | 0.110 |
Why?
| | Surgical Procedures, Operative | 1 | 2014 | 215 | 0.100 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2012 | 31 | 0.100 |
Why?
| | Diet, Mediterranean | 1 | 2012 | 21 | 0.100 |
Why?
| | History, 20th Century | 1 | 2013 | 281 | 0.100 |
Why?
| | Diet, Sodium-Restricted | 1 | 2012 | 34 | 0.100 |
Why?
| | Dietary Fiber | 1 | 2012 | 44 | 0.100 |
Why?
| | Clinical Competence | 2 | 2016 | 951 | 0.100 |
Why?
| | Diet, Fat-Restricted | 1 | 2012 | 76 | 0.100 |
Why?
| | Risk Factors | 2 | 2020 | 9000 | 0.100 |
Why?
| | Blood Transfusion | 1 | 2014 | 306 | 0.100 |
Why?
| | Forecasting | 1 | 2013 | 353 | 0.100 |
Why?
| | Empirical Research | 1 | 2011 | 25 | 0.100 |
Why?
| | Fruit | 1 | 2012 | 130 | 0.100 |
Why?
| | Vegetables | 1 | 2012 | 133 | 0.100 |
Why?
| | Dietary Proteins | 1 | 2012 | 130 | 0.100 |
Why?
| | Nomograms | 1 | 2011 | 48 | 0.100 |
Why?
| | Research | 1 | 2014 | 411 | 0.090 |
Why?
| | Self Care | 1 | 2013 | 357 | 0.090 |
Why?
| | Curriculum | 1 | 2016 | 910 | 0.090 |
Why?
| | Insurance Coverage | 1 | 2011 | 208 | 0.090 |
Why?
| | Polysaccharides | 1 | 2010 | 78 | 0.090 |
Why?
| | Time Factors | 1 | 2020 | 6412 | 0.090 |
Why?
| | Life Style | 1 | 2012 | 430 | 0.090 |
Why?
| | Pharmacy Service, Hospital | 1 | 2010 | 86 | 0.090 |
Why?
| | Patient Care Team | 1 | 2014 | 521 | 0.090 |
Why?
| | Complementary Therapies | 1 | 2010 | 71 | 0.090 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2010 | 111 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1185 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2014 | 687 | 0.080 |
Why?
| | Job Satisfaction | 1 | 2010 | 175 | 0.080 |
Why?
| | Colonic Neoplasms | 1 | 2010 | 224 | 0.080 |
Why?
| | Sulfonamides | 3 | 2020 | 445 | 0.080 |
Why?
| | Thrombin Time | 2 | 2020 | 11 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2007 | 72 | 0.080 |
Why?
| | Bariatric Surgery | 1 | 2010 | 166 | 0.080 |
Why?
| | Intensive Care Units | 2 | 2023 | 635 | 0.080 |
Why?
| | Delayed-Action Preparations | 1 | 2007 | 161 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 4708 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2020 | 422 | 0.070 |
Why?
| | Prostaglandins | 1 | 2006 | 78 | 0.070 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2006 | 60 | 0.070 |
Why?
| | Long QT Syndrome | 1 | 2006 | 57 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 439 | 0.070 |
Why?
| | Excipients | 1 | 2005 | 50 | 0.070 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2005 | 101 | 0.060 |
Why?
| | Animals | 5 | 2019 | 33381 | 0.060 |
Why?
| | beta-Alanine | 2 | 2014 | 20 | 0.060 |
Why?
| | Obesity | 2 | 2023 | 2746 | 0.060 |
Why?
| | Acute Disease | 2 | 2014 | 940 | 0.060 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 304 | 0.060 |
Why?
| | Thromboxane B2 | 1 | 2023 | 27 | 0.060 |
Why?
| | Benzimidazoles | 2 | 2014 | 140 | 0.060 |
Why?
| | Healthy Volunteers | 1 | 2023 | 201 | 0.050 |
Why?
| | Thinness | 1 | 2022 | 91 | 0.050 |
Why?
| | Pharmacokinetics | 1 | 2000 | 27 | 0.050 |
Why?
| | Disease Progression | 1 | 2007 | 2490 | 0.050 |
Why?
| | Thrombelastography | 1 | 2021 | 192 | 0.050 |
Why?
| | Professional Role | 2 | 2013 | 153 | 0.050 |
Why?
| | Aftercare | 1 | 2022 | 194 | 0.050 |
Why?
| | Allied Health Personnel | 1 | 2020 | 44 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 492 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 380 | 0.040 |
Why?
| | Hemostasis | 1 | 2019 | 70 | 0.040 |
Why?
| | Syndrome | 1 | 1998 | 344 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5116 | 0.040 |
Why?
| | Heart Failure | 1 | 2010 | 1969 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 598 | 0.040 |
Why?
| | Body Weight | 1 | 2021 | 934 | 0.040 |
Why?
| | Risk Assessment | 1 | 2006 | 3057 | 0.040 |
Why?
| | Quality of Life | 1 | 2007 | 2366 | 0.040 |
Why?
| | Calibration | 1 | 2016 | 135 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 796 | 0.030 |
Why?
| | Thiazoles | 1 | 2016 | 121 | 0.030 |
Why?
| | Body Mass Index | 1 | 2023 | 2092 | 0.030 |
Why?
| | Thromboplastin | 1 | 2014 | 68 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2014 | 238 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2014 | 187 | 0.030 |
Why?
| | Pyridines | 1 | 2016 | 440 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2424 | 0.030 |
Why?
| | Prospective Studies | 1 | 2023 | 6471 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2011 | 125 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 265 | 0.020 |
Why?
| | Pharmacy Administration | 1 | 2010 | 1 | 0.020 |
Why?
| | Societies, Pharmaceutical | 1 | 2010 | 28 | 0.020 |
Why?
| | Health Care Costs | 1 | 2013 | 394 | 0.020 |
Why?
| | Career Mobility | 1 | 2010 | 66 | 0.020 |
Why?
| | Awards and Prizes | 1 | 2010 | 57 | 0.020 |
Why?
| | Micronutrients | 1 | 2010 | 79 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 693 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 523 | 0.020 |
Why?
| | Food | 1 | 2010 | 162 | 0.020 |
Why?
| | Reward | 1 | 2010 | 209 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 571 | 0.020 |
Why?
| | Young Adult | 1 | 2023 | 10793 | 0.020 |
Why?
| | Length of Stay | 1 | 2011 | 1032 | 0.020 |
Why?
| | Patient Readmission | 1 | 2011 | 634 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2010 | 467 | 0.020 |
Why?
| | Motivation | 1 | 2010 | 506 | 0.020 |
Why?
| | Internet | 1 | 2010 | 633 | 0.020 |
Why?
|
|
Trujillo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|